Clinical trial
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young…
NCT00196924 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00196924 |
|---|---|
| Title | Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. |
| Official title | Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV-16/18 L1/AS04 |
| Enrollment | 2,067 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 23, 2017 |
| Countries | Australia, Colombia, Czechia, France, Germany, Honduras, Norway, Panama, South Korea, Spain, Sweden, Taiwan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: